Exhibit 99.1
CONTACT | ||
DR. REDDY'S LABORATORIES LTD. 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500034. Telangana, India. | Investor relationS | Media relationS |
Richa Periwal richaperiwal@drreddys.com | USHA IYER ushaiyer@drreddys.com |
Dr. Reddy’s Q3 & 9M FY23 Financial Results
Hyderabad, India, January 25, 2023: Dr. Reddy’s Laboratories Ltd. (BSE: 500124 | NSE: DRREDDY | NYSE: RDY | NSEIFSC: DRREDDY) today announced its consolidated financial results for the quarter and the nine months ended December 31, 2022. The information mentioned in this release is on the basis of consolidated financial statements under International Financial Reporting Standards (IFRS).
Q3 Performance Summary | 9M Performance Summary |
Rs. 6,770 Cr | Rs. 18,291 Cr |
Revenue | Revenue |
[Up: 27% YoY; Up: 7% QoQ] | [Up: 14% YoY] |
59.2% | 56.5% |
Gross Margin | Gross Margin |
[Q3 FY22: 53.8%; Q2 FY23: 59.1%] | [9M FY22: 53.2%] |
Rs.1,798 Cr | Rs. 5,003 Cr |
SGNA expenses | SGNA expenses |
[Up: 17% YoY; Up: 9% QoQ] | [Up: 8% YoY] |
Rs. 482 Cr | Rs. 1,402 Cr |
R&D expenses | R&D expenses |
[7.1% of Revenues] | [7.7% of Revenues] |
Rs. 1,966 Cr | Rs. 5,677 Cr |
EBITDA | EBITDA |
[29.0% of Revenues; Up: 55% YoY; Up: 2% QoQ] | [31.0% of Revenues; Up: 48% YoY] |
Rs. 1,635 Cr | Rs. 4,711 Cr |
Profit before Tax | Profit before Tax |
[Up: 68% YoY; Up: 1% QoQ] | [Up: 58% YoY] |
Rs. 1,247 Cr | Rs. 3,548 Cr |
Profit after Tax | Profit after Tax |
[Up: 77% YoY; Up: 12% QoQ] | [Up: 56% YoY] |
Commenting on the results, Co-chairman & MD, G V Prasad said “Our strong financial performance was supported by growth in the US and the Russia markets. We continue to strengthen our development pipeline to reach more patients globally.”
All amounts in millions, except EPS | All US dollar amounts based on convenience translation rate of 1 USD = Rs. 82.72 |
Dr. Reddy’s Laboratories Limited and Subsidiaries
Consolidated Income Statement
Q3 FY23 | Q3 FY22 | YoY | Q2 FY23 | QoQ | ||||||||||||||||||||||||||||
Particulars | ($) | (Rs.) | ($) | (Rs.) | Gr % | ($) | (Rs.) | Gr % | ||||||||||||||||||||||||
Revenues | 818 | 67,700 | 643 | 53,197 | 27 | 762 | 63,057 | 7 | ||||||||||||||||||||||||
Cost of Revenues | 334 | 27,607 | 297 | 24,585 | 12 | 312 | 25,810 | 7 | ||||||||||||||||||||||||
Gross Profit | 485 | 40,093 | 346 | 28,612 | 40 | 450 | 37,247 | 8 | ||||||||||||||||||||||||
Operating Expenses | ||||||||||||||||||||||||||||||||
Selling, General & Administrative expenses | 217 | 17,981 | 186 | 15,411 | 17 | 200 | 16,560 | 9 | ||||||||||||||||||||||||
Research and Development expenses | 58 | 4,821 | 50 | 4,159 | 16 | 59 | 4,869 | (1 | ) | |||||||||||||||||||||||
Impairment of non-current assets | 2 | 134 | 1 | 47 | 185 | 0 | 25 | 436 | ||||||||||||||||||||||||
Other operating expense/(income) | 9 | 732 | (3 | ) | (240 | ) | - | (4 | ) | (334 | ) | - | ||||||||||||||||||||
Results from operating activities | 199 | 16,425 | 112 | 9,235 | 78 | 195 | 16,127 | 2 | ||||||||||||||||||||||||
Net finance expense/(income) | 2 | 139 | (3 | ) | (289 | ) | - | 2 | 156 | (10 | ) | |||||||||||||||||||||
Share of profit of equity accounted investees | (1 | ) | (60 | ) | (2 | ) | (185 | ) | (68 | ) | (2 | ) | (140 | ) | (57 | ) | ||||||||||||||||
Profit before Income Tax | 198 | 16,346 | 117 | 9,709 | 68 | 195 | 16,111 | 1 | ||||||||||||||||||||||||
Income Tax | 47 | 3,875 | 32 | 2,644 | 47 | 60 | 4,983 | (22 | ) | |||||||||||||||||||||||
Profit for the period | 151 | 12,471 | 85 | 7,065 | 77 | 135 | 11,128 | 12 | ||||||||||||||||||||||||
Diluted Earnings Per Share (EPS) | 0.91 | 74.95 | 0.51 | 42.48 | 76 | 0.81 | 66.89 | 12 |
As % to revenues | Q3 FY23 | Q3 FY22 | Q2 FY23 | |||||||||
Gross Profit | 59.2 | 53.8 | 59.1 | |||||||||
SG&A | 26.6 | 29.0 | 26.3 | |||||||||
R&D | 7.1 | 7.8 | 7.7 | |||||||||
EBITDA | 29.0 | 23.8 | 30.6 | |||||||||
PBT | 24.1 | 18.3 | 25.5 | |||||||||
PAT | 18.4 | 13.3 | 17.6 |
EBITDA Computation
Q3 FY23 | Q3 FY22 | Q2 FY23 | ||||||||||||||||||||||
Particulars | ($) | (Rs.) | ($) | (Rs.) | ($) | (Rs.) | ||||||||||||||||||
Profit before Income Tax | 198 | 16,346 | 117 | 9,709 | 195 | 16,111 | ||||||||||||||||||
Interest income (net)* | (1 | ) | (93 | ) | (1 | ) | (72 | ) | 1 | 61 | ||||||||||||||
Depreciation | 27 | 2,245 | 25 | 2,066 | 25 | 2,107 | ||||||||||||||||||
Amortization | 12 | 1,026 | 11 | 910 | 12 | 1,018 | ||||||||||||||||||
Impairment | 2 | 134 | 1 | 47 | 0 | 25 | ||||||||||||||||||
EBITDA | 238 | 19,658 | 153 | 12,659 | 234 | 19,322 |
* Includes income from Investments
All amounts in millions, except EPS | All US dollar amounts based on convenience translation rate of 1 USD = Rs. 82.72 |
Key Balance Sheet Items
As on 31st Dec 2022 | As on 30th Sep 2022 | As on 31st Dec 2021 | ||||||||||||||||||||||
Particulars | ($) | (Rs.) | ($) | (Rs.) | ($) | (Rs.) | ||||||||||||||||||
Cash and cash equivalents and current investments | 606 | 50,164 | 354 | 29,306 | 454 | 37,556 | ||||||||||||||||||
Trade receivables (current & non-current) | 907 | 75,046 | 931 | 76,987 | 756 | 62,507 | ||||||||||||||||||
Inventories | 596 | 49,326 | 593 | 49,042 | 601 | 49,675 | ||||||||||||||||||
Property, plant and equipment | 786 | 64,996 | 771 | 63,817 | 761 | 62,971 | ||||||||||||||||||
Goodwill and Other Intangible assets | 428 | 35,401 | 436 | 36,084 | 442 | 36,581 | ||||||||||||||||||
Loans and borrowings (current & non-current) | 214 | 17,663 | 209 | 17,289 | 340 | 28,164 | ||||||||||||||||||
Trade payables | 315 | 26,023 | 275 | 22,778 | 296 | 24,492 | ||||||||||||||||||
Equity | 2,663 | 2,20,273 | 2,493 | 2,06,225 | 2,297 | 1,90,016 |
Revenue Mix by Segment
Q3 FY23 | Q3 FY22 | YoY | Q2 FY23 | QoQ | ||||||||||||||||
Segment | (Rs.) | (Rs.) | Gr % | (Rs.) | Gr % | |||||||||||||||
Global Generics | 59,241 | 44,508 | 33 | 55,946 | 6 | |||||||||||||||
North America | 30,567 | 18,645 | 64 | 28,001 | 9 | |||||||||||||||
Europe | 4,303 | 4,058 | 6 | 4,199 | 2 | |||||||||||||||
India | 11,274 | 10,266 | 10 | 11,500 | (2 | ) | ||||||||||||||
Emerging Markets | 13,097 | 11,539 | 14 | 12,246 | 7 | |||||||||||||||
Pharmaceutical Services and Active Ingredients (PSAI) | 7,758 | 7,271 | 7 | 6,434 | 21 | |||||||||||||||
Others | 701 | 1,418 | (51 | ) | 677 | 4 | ||||||||||||||
Total | 67,700 | 53,197 | 27 | 63,057 | 7 |
Revenue Analysis
Global Generics (GG)
Revenues from GG segment at Rs. 59.2 billion:
Ø | Year-on-year growth of 33% and sequential quarter growth of 6% was primarily driven by new product launches, increase in volumes of our base business and favorable forex movement, offset partially due to price erosion in our generic markets. |
North America
Revenues from North America at Rs. 30.6 billion:
Ø | Year-on-year growth of 64%, driven by new products launches, increase in volumes and a favorable forex movement, which was partly offset by price erosion. |
Ø | Sequential growth of 9%, driven by increase in volumes partly offset by price erosion in some products. |
Ø | We launched five new products in US during the quarter. These were desmopressin MDV, OTC guaifenesin ER, fingolimod capsules, thiotepa injection and biorphen injection. |
Ø | We filed one new ANDA during the quarter. As of 31st December 2022, cumulatively 78 generic filings are pending for approval with the USFDA (75 ANDAs and 3 NDAs under 505(b)(2) route). Out of these 78 pending filings, 41 are Para IVs and we believe 21 have ‘First to File’ status. |
Europe
Revenues from Europe at Rs. 4.3 billion:
Ø | Year-on-year growth of 6%, driven by new product launches, increase in volumes which was partly offset by price erosion and adverse forex rates. Sequential growth of 2%, driven by new product launches and favorable forex movement, and was partly offset by reduction in volumes of certain products. |
Ø | Revenues from Germany at Rs. 2.2 billion. Year-on-year decline of 1% and sequential decline of 6%. |
Ø | Revenues from UK/OL at Rs. 1.3 billion. Year-on-year growth of 25% and sequential growth of 16%. |
Ø | Revenues from other European countries at Rs. 0.8 billion. Year-on-year growth of 3% and sequential growth of 8%. |
India
Revenues from India at Rs. 11.3 billion:
Ø | Year-on-year growth of 10%, driven by increase in sales prices and new product launches, partly offset by reduction in volumes for certain products. |
Ø | Sequential decline of 2%, primarily due to reduction in volumes of certain products. |
Emerging Markets
Revenues from Emerging Markets at Rs. 13.1 billion. Year-on-year growth of 14% and sequential quarter growth of 7%:
Ø | Revenues from Russia at Rs. 6.9 billion. Year-on-year growth of 45% was on account of increase in volumes and prices, new product launches, and favorable forex rates. Sequential quarter growth of 16% was primarily on account of increase in volumes. |
Ø | Revenues from other CIS countries and Romania at Rs. 2.2 billion. Year-on-year decline of 6% was due to reduction in volumes and adverse forex movement, partly offset by increase in sales price of some products and new product launches. Sequential quarter growth of 4% was driven by new product launches and favorable forex movement. |
Ø | Revenues from Rest of World (RoW) territories at Rs. 4.0 billion. Year-on-year decline of 10% was on account of higher base in previous year due to the covid product sales and decrease in sales price of some of our key molecules, which was partly offset by new product launches. Sequential decline of 4% was on account of decrease in sales price of some products, which was partly offset by new product launches and favorable forex movement. |
Pharmaceutical Services and Active Ingredients (PSAI)
Revenues from PSAI at Rs. 7.8 billion:
Ø | Year-on-year growth of 7% was driven by favorable forex movement and increase in volumes partly offset by price erosion. |
Ø | Sequential growth of 21% was driven by increase in volumes and new product launches. |
Ø | During the quarter we filed two DMFs in the US. |
Income Statement Highlights:
Ø | Gross profit margin at 59.2%: |
· | Increased by ~545 bps over previous year driven mainly due to new product launches with higher margins, favorable products mix and favorable forex movement which was partly offset by price erosion. Margins have marginally increased by 15 bps sequentially. |
· | Gross profit margin for GG and PSAI business segments are at 64.6% and 18.2% respectively. |
Ø | SG&A expenses at Rs. 18.0 billion, increased by 17% year-on-year. This increase was primarily attributable to investments in sales & marketing, annual increments, certain one-off expenses and higher forex rate. Sequentially the SG&A expenses increased by 9% mainly due to increase in sales & marketing spends and other one-off expenses. |
Ø | R&D expenses at Rs. 4.8 billion. As % to revenues - Q3 FY23: 7.1% | Q2 FY23: 7.7% | Q3 FY22: 7.8%. We continue our focus on investing in R&D to build a healthy pipeline of new products across our markets including development of products in our biosimilars and generics businesses. |
Ø | Impairment charge of Rs. 134 million as compared to Rs. 47 million charge in Q3 FY22. |
Ø | Other operating expense at Rs. 732 million compared to income of Rs. 240 million in Q3 FY22. Net other expense during the quarter included the loss on sale of asset at Leiden, Netherlands. |
Ø | Net Finance expense at Rs. 139 million compared to income of Rs. 289 million in Q3 FY22. |
Ø | Profit before Tax at Rs. 16.3 billion, which is 24.1% of revenues. The profit before tax increased by 68% year-on-year and by 1% sequentially. |
Ø | Profit after Tax at Rs. 12.5 billion. The effective tax rate is ~23.7% for the quarter. |
Ø | Diluted earnings per share is at Rs. 74.95. |
Other Highlights:
Ø | EBITDA at Rs. 19.7 billion and the EBITDA margin is 29.0%. |
Ø | Capital expenditure is at Rs. 2.9 billion. |
Ø | Free cash-flow is at Rs. 19.8 billion. |
Ø | Net cash surplus for the company is at Rs. 34.0 billion as on December 31, 2022. Consequently, net debt to equity ratio is (0.15). |
Ø | ROCE for the company is 35.8% (annualized). |
Earnings Call Details (07:00 pm IST, 08:30 am EST, Jan 25, 2023)
The management of the Company will host an earnings call to discuss the Company’s financial performance and answer any questions from the participants.
Conference Joining Information |
Option 1: Express Join with DiamondPass™ |
Pre-register with the below link and join without waiting for the operator. https://services.choruscall.in/DiamondPassRegistration/register?confirmationNumber=8738288&linkSecurityString=2a8516a7d0
Option 2: Join through below Dial-In Numbers | |
Universal Access Number:
| +91 22 6280 1219 +91 22 7115 8120 |
International Toll Free Number: | USA: 1 866 746 2133 UK: 0 808 101 1573 Singapore: 800 101 2045 Hong Kong: 800 964 448 |
No password/pin number is necessary to dial in to any of the above numbers. The operator will provide instructions on asking questions before and during the call.
Play Back: The play back will be available after the earnings call, till January 31st, 2023. For play back dial in phone No: +91 22 7194 5757, and Playback Code is 54421.
Transcript: Transcript of the Earnings call will be available on the Company’s website: www.drreddys.com
About Dr. Reddy’s: Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) is an integrated pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its businesses, Dr. Reddy’s offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations. Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Dr Reddy’s operates in markets across the globe. Our Major markets include – USA, India, Russia & CIS countries, and Europe. For more information, log on to: www.drreddys.com
Disclaimer: This press release may include statements of future expectations and other forward-looking statements that are based on the management’s current views and assumptions and involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. In addition to statements which are forward-looking by reason of context, the words "may", "will", "should", "expects", "plans", "intends", "anticipates", "believes", "estimates", "predicts", "potential", or "continue" and similar expressions identify forward-looking statements. Actual results, performance or events may differ materially from those in such statements due to without limitation, (i) general economic conditions such as performance of financial markets, credit defaults , currency exchange rates , interest rates , persistency levels and frequency / severity of insured loss events (ii) mortality and morbidity levels and trends, (iii) changing levels of competition and general competitive factors, (iv) changes in laws and regulations and in the policies of central banks and/or governments, (v) the impact of acquisitions or reorganization, including related integration issues, and (vi) the susceptibility of our industry and the markets addressed by our, and our customers’, products and services to economic downturns as a result of natural disasters, epidemics, pandemics or other widespread illness, including coronavirus (or COVID-19), and (vii) other risks and uncertainties identified in our public filings with the Securities and Exchange Commission, including those listed under the "Risk Factors" and "Forward-Looking Statements" sections of our Annual Report on Form 20-F for the year ended March 31, 2022. The company assumes no obligation to update any information contained herein.”